Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07128355 · ClinicalTrials.gov registry record · Early Phase 1
Botensilimab, Balstilimab, and SBRT in Colorectal Cancer
A Early Phase 1 study, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 15
- Enrollment target
NCT07128355: Recruiting Early Phase 1 study, sponsored by Massachusetts General Hospital.
NCT07128355 is a Early Phase 1 study that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 15 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07128355, a Early Phase 1 study, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
This is a single-arm pilot feasibility study evaluating the combination of Botensilimab and Balstilimab with Radiation Therapy (RT) in Non-Microsatellite Instability High (MSI-H) or Proficient Mismatch Repair (pMMR) chemorefractory colorectal cancer (CRC) with liver metastasis.
Interventions
- DRUG Balstilimab
- RADIATION Stereotactic Body Radiation Therapy (SBRT)
- DRUG Botensilimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2026-05-12 |
| Est. Completion | 2027-09 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07128355
The ClinicalTrials.gov registry entry for NCT07128355 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Balstilimab is the first listed.
NCT07128355 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07128355 about?
NCT07128355 is a clinical study titled "Botensilimab, Balstilimab, and SBRT in Colorectal Cancer". This is a single-arm pilot feasibility study evaluating the combination of Botensilimab and Balstilimab with Radiation Therapy (RT) in Non-Microsatellite Instability High (MSI-H) or Proficient Mismatch Repair (pMMR) chemorefractory colorectal cancer (CRC) with liver metastasis.
What is the current status of trial NCT07128355?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 15 participants. The study started on 2026-05-12. Estimated completion is 2027-09.
What interventions are being tested in trial NCT07128355?
The interventions under investigation include: Balstilimab (DRUG), Stereotactic Body Radiation Therapy (SBRT) (RADIATION), Botensilimab (DRUG).
Who is sponsoring clinical trial NCT07128355?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.